Organon & Co (OGN) - Net Assets
Based on the latest financial reports, Organon & Co (OGN) has net assets worth $906.00 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.55 Billion) and total liabilities ($12.65 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OGN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $906.00 Million |
| % of Total Assets | 6.69% |
| Annual Growth Rate | -35.15% |
| 5-Year Change | -91.4% |
| 10-Year Change | N/A |
| Growth Volatility | 59.0 |
Organon & Co - Net Assets Trend (2018–2024)
This chart illustrates how Organon & Co's net assets have evolved over time, based on quarterly financial data. Also explore Organon & Co assets under control for the complete picture of this company's asset base.
Annual Net Assets for Organon & Co (2018–2024)
The table below shows the annual net assets of Organon & Co from 2018 to 2024. For live valuation and market cap data, see OGN company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $472.00 Million | +774.29% |
| 2023-12-31 | $-70.00 Million | +92.15% |
| 2022-12-31 | $-892.00 Million | +40.85% |
| 2021-12-31 | $-1.51 Billion | -127.49% |
| 2020-12-31 | $5.49 Billion | -22.02% |
| 2019-12-31 | $7.04 Billion | +10.82% |
| 2018-12-31 | $6.35 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Organon & Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $906.00 Million | 100.00% |
| Total Equity | $906.00 Million | 100.00% |
Organon & Co Competitors by Market Cap
The table below lists competitors of Organon & Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chow Tai Seng Jewellery Co Ltd
SHE:002867
|
$2.11 Billion |
|
Hunan Zhongke Electric
SHE:300035
|
$2.11 Billion |
|
Compania Cervecerias Unidas SA
SN:CCU
|
$2.11 Billion |
|
Ruentex Development Co Ltd
TW:9945
|
$2.11 Billion |
|
Russel Metals Inc.
TO:RUS
|
$2.10 Billion |
|
Elekta AB (publ)
ST:EKTA-B
|
$2.10 Billion |
|
AUB Group Ltd
AU:AUB
|
$2.10 Billion |
|
Shandong Dawn Polymer Co Ltd
SHE:002838
|
$2.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Organon & Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 472,000,000 to 906,000,000, a change of 434,000,000 (91.9%).
- Net income of 187,000,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 1,555,000,000.
- Other factors decreased equity by 1,308,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $187.00 Million | +20.64% |
| Other Comprehensive Income | $1.55 Billion | +171.63% |
| Other Changes | $-1.31 Billion | -144.37% |
| Total Change | $- | 91.95% |
Book Value vs Market Value Analysis
This analysis compares Organon & Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.53x to 3.83x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $25.08 | $13.29 | x |
| 2019-12-31 | $27.79 | $13.29 | x |
| 2020-12-31 | $21.64 | $13.29 | x |
| 2021-12-31 | $-5.95 | $13.29 | x |
| 2022-12-31 | $-3.50 | $13.29 | x |
| 2023-12-31 | $-0.27 | $13.29 | x |
| 2024-12-31 | $1.82 | $13.29 | x |
| 2025-12-31 | $3.47 | $13.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Organon & Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.64%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.01%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (20.64%) is below the historical average (40.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 33.92% | 22.02% | 0.93x | 1.65x | $1.52 Billion |
| 2019 | 45.74% | 41.38% | 0.74x | 1.50x | $2.51 Billion |
| 2020 | 39.37% | 33.07% | 0.65x | 1.84x | $1.61 Billion |
| 2021 | 0.00% | 21.43% | 0.59x | 0.00x | $1.50 Billion |
| 2022 | 0.00% | 14.85% | 0.56x | 0.00x | $1.01 Billion |
| 2023 | 0.00% | 16.33% | 0.52x | 0.00x | $1.03 Billion |
| 2024 | 183.05% | 13.49% | 0.49x | 27.76x | $816.80 Million |
| 2025 | 20.64% | 3.01% | 0.00x | 0.00x | $96.40 Million |
Industry Comparison
This section compares Organon & Co's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $16,889,815,400
- Average return on equity (ROE) among peers: 31.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Organon & Co (OGN) | $906.00 Million | 33.92% | 13.96x | $2.11 Billion |
| AbbVie Inc (ABBV) | $4.49 Billion | 91.90% | 5.50x | $365.30 Billion |
| Amgen Inc (AMGN) | $25.78 Billion | 20.01% | 1.68x | $177.77 Billion |
| Amarin Corporation PLC (AMRN) | $667.10 Million | 1.16% | 0.60x | $292.71 Million |
| AstraZeneca PLC (AZN) | $23.95 Billion | 26.05% | 1.24x | $286.40 Billion |
| Biogen Inc (BIIB) | $5.81 Billion | 13.49% | 0.46x | $27.45 Billion |
| Bristol-Myers Squibb Company (BMY) | $12.21 Billion | 42.98% | 1.42x | $118.52 Billion |
| Gilead Sciences Inc (GILD) | $1.87 Billion | 24.02% | 0.15x | $163.34 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $8.32 Billion | 55.33% | 3.74x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $70.42 Billion | 23.49% | 1.01x | $547.37 Billion |
| Eli Lilly and Company (LLY) | $15.39 Billion | 15.53% | 1.36x | $862.20 Billion |
About Organon & Co
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a… Read more